Pharmaceutical giant AstraZeneca has announced a remarkable 40% increase in annual profits, fueled by robust demand for its cancer treatments and strategic expansions into key global markets. The FTSE 100 firm reported pre-tax profits of $12.4 billion (£9.06 billion) for 2025, a significant rise from $8.69 billion (£6.35 billion) in 2024, with a notable 49% jump in the fourth quarter on a constant currency basis.
Financial Performance and Outlook
Operating profits surged by 36% on a constant currency basis to $13.74 billion (£10.04 billion), while revenues increased by 8% to $58.74 billion (£42.93 billion) after adjusting for exchange rates. AstraZeneca forecasts that revenues will grow by a mid-to-high single-digit percentage in 2026, with underlying earnings per share expected to rise by a low double-digit percentage.
Strategic Focus on Cancer and Weight-Loss Drugs
The Anglo-Swedish group is banking on sustained strong demand for its cancer drugs while aggressively pushing into the US and Chinese markets. Additionally, the company is investing heavily in the burgeoning weight-loss medication sector, aiming to offset the impact of losing patent protection on its top-selling diabetes drug, Farxiga. Sales growth for Farxiga was modest at 2% in the fourth quarter on a constant currency basis.
Chief Executive Pascal Soriot reaffirmed the company's ambitious target of achieving $80 billion (£58.47 billion) in annual sales by 2030 through new medicines and strategic investments. AstraZeneca plans to report results from up to 20 advanced clinical trials this year, with Soriot stating, "The momentum across our company is continuing in 2026." He highlighted over 100 Phase 3 studies underway, including transformative technologies that could revolutionize patient outcomes and drive growth beyond 2030.
Expansion and Investment Initiatives
In a significant move, AstraZeneca recently entered into an $18.5 billion (£13.52 billion) partnership with China's CSPC Pharmaceutical Group to accelerate the development of experimental weight-loss and diabetes drugs. This investment positions the company to compete in a fast-growing market currently dominated by blockbuster brands like Mounjaro, Ozempic, and Wegovy.
The company generates nearly half of its revenues in the US and is targeting further expansion in the world's largest pharmaceutical market. Last July, AstraZeneca announced plans to invest approximately $50 billion (£36.55 billion) by 2030, with joint ventures in China aimed at capturing opportunities in the world's second-largest economy.
Market Reaction and Analyst Insights
Following the announcement, AstraZeneca's shares edged 1% higher in morning trading on Tuesday, building on a 28% rise over the past six months. The company has also begun trading shares on the NYSE this month, while maintaining its listings on the London Stock Exchange and Nasdaq Stockholm.
Chris Beauchamp, chief market analyst at IG, commented, "The numbers this morning continue to show how AstraZeneca seems to have its house in order when it comes to its drug pipeline. The outlook and recent performance more than justifies the recent surge in the share price, which has finally seen it break higher after years of sideways trading."
This strong financial performance underscores AstraZeneca's strategic focus on innovation and global market expansion, positioning it for sustained growth in the competitive pharmaceutical industry.
